Biotech

Vital Therapies (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the fourth quarter and fiscal year ended December 31, 2017. As quoted in the press release: “As VTL-308 nears completion, I am proud of the job our team has done in …

Vital Therapies (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the fourth quarter and fiscal year ended December 31, 2017.

As quoted in the press release:

“As VTL-308 nears completion, I am proud of the job our team has done in designing and running this pivotal trial,” said Russell J. Cox, the Company’s Chief Executive Officer. “Not only do baseline characteristics of subjects continue to track closely to the reference population, but also, blended event rates were found to be consistent with our modeled expectations. We look forward to reporting topline results in the third quarter, and in the event of a positive outcome, preparing to file a biologics license application next year.”

Click here to read the full press release.

MARKETS

Markets
TSX19669.17+49.04
TSXV668.28+4.11
DOW32832.54+29.07
S&P 5004140.06-5.13
NASD12644.46-13.10
ASX7015.60+40.70

COMMODITIES

Commodities
Gold1789.00+14.90
Silver20.70+0.88
Copper3.580.00
Palladium2242.50+126.50
Platinum944.50+12.50
Oil90.69-0.07
Heating Oil3.19+0.01
Natural Gas7.66+0.07

DOWNLOAD FREE REPORTS

×